2-Methoxypyridine 98%

Teriflunomide has been used as a dihydroorotate dehydrogenase (DHODH) inhibitor.

For R&D use onlynot for drug household or other uses.

Teriflunomide (trade name Aubagio marketed by Sanofi) is the active metabolite of leflunomide. Teriflunomide was investigated in the Phase III clinical trial TEMSO as a medication for multiple sclerosis (MS). The study was completed in July 2010. 2-year results were positive. However the subsequent TENERE head-to-head comparison trial reported that although permanent discontinuations [of therapy] were substantially less common among MS patients who received teriflunomide compared with interferon beta-1a relapses were more common with teriflunomide. The drug was approved by the FDA on September 13 2012 and in the European Union on August 26 2013.